Last reviewed · How we verify

NCT04264624: GBT2017

Efficacy of Sub-gingival Air-polishing With Erythritol in the Treatment of Periodontitis

Completed NA Last updated 18 February 2020
What this trial tests

NA trial testing Perioflow and Erythritol powder and ultrasonic debridement in Periodontitis, Adult in 40 participants. Completed in 10 December 2019.

Timeline
28 February 2018
Primary endpoint
5 October 2019
10 December 2019

Quick facts

Lead sponsorAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment40
Start date28 February 2018
Primary completion5 October 2019
Estimated completion10 December 2019
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia — full company profile →

Who can join

Adults 18 to 75, any sex, with Periodontitis, Adult or Periodontitis, Aggressive. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The first step in the management of periodontal disease involves the non-surgical removal of the soft and hard bacterial deposits at all supra- and sub-gingival sites, especially into deep pockets, which can be carried on with different instruments. Unfortunately it seems that, after the initial therapy, many patients still present with active pockets (residual pockets) requiring further treatment and posing a risk of disease progression. This might be due to limitations of the instruments applied and patient-related factors. Air-polishing with low-abrasiveness powders seems to be very effective in the removal of supra- and sub-gingival biofilm and could provide additional benefits during the treatment of pockets. The hypothesis of the present randomized controlled trial was that the adjunctive use of a sub-gingival nozzle for air-polishing with erythritol powder in pockets with probing depth of 5-9mm and with bleeding (experimental sites) can bring clinical and microbiological advantages during the active therapy of periodontal disease, and reduce the number of residual pockets. To test this hypothesis, the patients, upon initial evaluation, were divided in 2 study groups: 1. The control group, undergoing a standard procedure involving air-polishing supra-gingivally and at healthy sub-gingival sites followed by debridement with an ultrasonic scaler at deep pathological pockets 2. The study group, undergoing the same procedure but with the additional use of a sub-gingival nozzle at deep pathological pockets. The healing of the experimental sites and the prevalence of residual pockets will be evaluated at 3 months after the initial therapy and compared between the two groups.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Efficacy of the additional use of subgingival air polishing with erythritol powder in the treatment of periodontitis patients: a randomized controlled clinical trial.
    Mensi M, Scotti E, Sordillo A, Calza S, et al · · 2021 · cited 19× · PMID 33404760 · DOI 10.1007/s00784-020-03648-z
  2. Efficacy of the additional use of subgingival air-polishing with erythritol powder in the treatment of periodontitis patients: a randomized controlled clinical trial. Part II: effect on sub-gingival microbiome.
    Mensi M, Caselli E, D'Accolti M, Soffritti I, et al · · 2023 · cited 10× · PMID 36538094 · DOI 10.1007/s00784-022-04811-4

Verify or expand the search:

Other recruiting trials for Periodontitis, Adult

Currently open trials in the same condition.

Other Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04264624.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing